Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors

Chauhan, Richa; Sazawal, Sudha; Pati, Haraprasad

doi:10.1007/s12288-018-0933-1

Cited by 5 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, molecular monitoring of PCR-ABL1 by reverse transcriptase quantitative PCR (RT-qPCR) is done at regular intervals. 22 In the present study, treatment response was achieved in 80% of patients with CML. Responders had significantly lower Sokal score when compared with non-responders in agreement with previous reports.…”

Section: Discussionsupporting

confidence: 48%

See 1 more Smart Citation

Circulating Mir-146A Expression Predicts Early Treatment Response to Imatinib in Adult Chronic Myeloid Leukemia

Habib

Nosiar

Eid

et al. 2021

Journal of Investigative Medicine

View full text Add to dashboard Cite

This study aimed to investigate the prognostic role of circulating miR-146a in the prediction of early response to imatinib treatment in patients with chronic myeloid leukemia (CML). Sixty patients with CML and 20 healthy controls were recruited in this study. BCR-ABL was assessed by quantitative rt-PCR at days 0 and 90 of imatinib therapy. Circulating miR-146a levels were assessed by quantitative rt-PCR at days 0, 14 and 90 of imatinib therapy for patients and once for controls. At day 90 of treatment, treatment response was achieved in 48 patients (80.0%). Responders had significantly lower baseline Sokal score when compared with non-responders. They also had significantly lower BCR-ABL expression at day 90 of treatment. The circulating miR-146a level was significantly lower in patients with CML than in healthy subjects and showed a significant rise after 14 days of imatinib treatment and an inverse correlation with BCR-ABL expression levels at 90 days. Using multivariate logistic regression analysis, baseline BCR-ABL (%) (OR (95% CI) 1.09 (1.03 to 1.016), p=0.006) and miR-146a at 14 days (OR (95% CI) 0.002 (0.0 to 0.09), p=0.001) were significant predictors of treatment response. Using ROC curve analysis, it was found that miR-146a expression at 14 and 90 days could distinguish responders from non-responders (AUC (95% CI) 0.849 (0.733 to 0.928) and 0.867 (0.755 to 0.941), respectively). This study reported for the first time that measurement of the circulating miR-146a expression at 14 days can predict the early response to imatinib treatment in patients with CML. Thus, this work indicates that miR-146a should be investigated in the setting of treatment response to other tyrosine kinase inhibitors.

show abstract

Section: Discussionsupporting

confidence: 48%

“…Hence, a more appropriate intervention can be applied in a suitable time such as increasing the therapeutic dose or changing to another type of TKIs. Thus, molecular monitoring of PCR-ABL1 by reverse transcriptase quantitative PCR (RT-qPCR) is done at regular intervals 22…”

Section: Discussionmentioning

confidence: 99%

Circulating Mir-146A Expression Predicts Early Treatment Response to Imatinib in Adult Chronic Myeloid Leukemia

Habib

Nosiar

Eid

et al. 2021

Journal of Investigative Medicine

View full text Add to dashboard Cite

show abstract

“…According to worldwide cancer data by the American Institute for Cancer Research, the global incidence of CML ranges from 0.7 per 100,000 to 1.5 per 100,000 persons. The lowest incidence is in Sweden therapy, considered the first-line treatment for newly diagnosed CML 2,3 and China, and the highest in Switzerland and the United States. 4 CML is an age-related disease that commonly affects the elderly (6 years old) in western countries and 50 years in Africa and Asia.…”

Section: Introductionmentioning

confidence: 99%

Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features

Ahmed

Khaleel

Fadhel

et al. 2022

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML), is one of the myeloproliferative disorders with a characteristic cytogenetic abnormality resulting in the BCR-ABL fusion gene. Imatinib Mesylate is an effective agent for treating patients in all stages of CML. According to the annual Iraqi cancer registry 2019, the total number of chronic myeloproliferative disorders was 338. The percentage and incidence rates were 0.94% and 0.86%, respectively, with a higher incidence rate in males than females (1.12 in males and 0.60 in females). In this registry, no details about CML, so this study aimed to estimate the number of CML patients who attended the national center of hematology from 2005 until 2020 and investigate their epidemiological and clinic-pathological data. All data were obtained from the National Center of Hematology /Baghdad. Data regarding annual admission, number of deaths, and information about age, regions, and sex, were collected from patient cards. Interview and history taking from the patient and reviewing their clinical features at diagnosis were performed, and then statistical analysis was achieved. Two hundred sixteen patients were registered as CML; among them, 163 are still alive, while 53 died. The mean age at diagnosis was 40.39 ±14.30, with a male-to-female ratio of 1:1.16. The pediatrics age group comprises 3.7% of total cases and 1.8 % and 9.4% in the alive and dead groups, respectively. The percentages of death were higher in the pediatric age group, 62,5%( 5 /8), followed by the patient group who were ≥60 years, 42.1%(8/19), while it was the least in adults < 60 years, 21.1% (40/189). In conclusion, the studied patients with CML were younger than the globally reported ages at diagnosis, with predominant female patients. Females had better survival, while children and the elderly were the worse. Most patients were symptomatic at diagnosis; however, a good outcome is achieved when treated with IM. Keywords: CML, Imatinib, leukemia,

show abstract

“…Chronic myeloid leukemia (CML) is a malignant disease of the blood-forming cells of the bone marrow [13]. The disease is characterized by the presence of the fusion gene BCR-ABL1 in immature myeloid cells [14].…”

Section: Introductionmentioning

confidence: 99%

Age- and gender-independent association of glutathione S-transferase null polymorphisms with chronic myeloid leukemia

Muddathir

Abdallah

Khabour

et al. 2019

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

The glutathione S-transferase (GST) genes encode enzymes that mediate the detoxification of xenobiotics by catalyzing the conjugation of glutathione (GSH) to xenobiotic substrates. The aim of the current study is to investigate the association between GSTT1 and GSTM1 polymorphisms and chronic myeloid leukemia (CML) among Sudanese patients. Patients with CML (n = 115) were recruited to the study from the Radiation and Isotope Centre Khartoum (RICK)-Sudan. Healthy individuals (n = 104) were included as controls. Genotyping of GSTT1 and GSTM1 polymorphisms was performed using multiplex PCR. Null deletions in the GSTT1 and GSTM1 genes are common in the Sudanese population (control group), with frequencies of 33.9% and 38.2%, respectively. The frequencies of GSTT1 (OR: 3.25, 95% CI: 1.87–5.65, p < 0.001) and GSTM1 (OR: 2.14, 95% CI: 1.25–3.67, p < 0.005) null genotypes were significantly higher in CML patients vs. controls. The distribution of GSTT1 and GSTM1 null polymorphisms was not different between male and female (p > 0.01) and young and old CML patients (p > 0.05). Hematological parameters were not affected by null polymorphisms in the patient group (p > 0.05). In addition, the frequency of GSTM1 null polymorphism was lower in advanced-phase CML patients compared to chronic-phase patients (p < 0.05). The GSTT1 and GSTM1 null polymorphisms are associated with CML among Sudanese patients, independently of their age and gender.

show abstract

Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors

Cited by 5 publications

References 38 publications

Circulating Mir-146A Expression Predicts Early Treatment Response to Imatinib in Adult Chronic Myeloid Leukemia

Circulating Mir-146A Expression Predicts Early Treatment Response to Imatinib in Adult Chronic Myeloid Leukemia

Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features

Age- and gender-independent association of glutathione S-transferase null polymorphisms with chronic myeloid leukemia

Contact Info

Product

Resources

About